Pelgraz (Pegfilgrastim)▼
Pelgraz ® is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). Link to Abbreviated Prescribing Info available below.
API Documents
Patient Information Leaflets (PILs)
You can report side effects directly via the HPRA website www.hpra.ie, by emailing the HPRA Pharmacovigilance department at [email protected], or by calling the HPRA on 01-676 4971.
Please also report side effects to Accord Healthcare Ireland Ltd, by calling 0044 (0) 1271 385257. By reporting side effects you can help provide more information on the safety of this medicine.
Medicinal product subject to medical prescription (POM).
Information placed on this digital platform is not intended as a substitute for consultation with your healthcare professional. Please consult your healthcare professional for further information.
Reporting of side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the HPRA website www.hpra.ie, by emailing the HPRA Pharmacovigilance department at [email protected], or by calling the HPRA on 01-676 4971.
Please also report side effects to Accord Healthcare Ireland Ltd, by calling 0044 (0) 1271 385257.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.
By reporting side effects you can help provide more information on the safety of this medicine.
